- Home
- RMCO vs EDSA Comparison
RMCO vs EDSA Comparison
Compare RMCO & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- EDSA
- Stock Information
- Founded
- RMCO 2021
- EDSA 2015
- Country
- RMCO United States
- EDSA Canada
- Employees
- RMCO N/A
- EDSA N/A
- Industry
- RMCO Multi-Sector Companies
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- EDSA Health Care
- Exchange
- RMCO Nasdaq
- EDSA Nasdaq
- Market Cap
- RMCO 14.9M
- EDSA 13.8M
- IPO Year
- RMCO N/A
- EDSA N/A
- Fundamental
- Price
- RMCO $1.33
- EDSA $2.09
- Analyst Decision
- RMCO
- EDSA Strong Buy
- Analyst Count
- RMCO 0
- EDSA 2
- Target Price
- RMCO N/A
- EDSA $13.00
- AVG Volume (30 Days)
- RMCO 113.3K
- EDSA 13.1K
- Earning Date
- RMCO 08-14-2025
- EDSA 08-08-2025
- Dividend Yield
- RMCO 0.20%
- EDSA N/A
- EPS Growth
- RMCO N/A
- EDSA N/A
- EPS
- RMCO N/A
- EDSA N/A
- Revenue
- RMCO $1,568,212.00
- EDSA N/A
- Revenue This Year
- RMCO N/A
- EDSA N/A
- Revenue Next Year
- RMCO N/A
- EDSA N/A
- P/E Ratio
- RMCO N/A
- EDSA N/A
- Revenue Growth
- RMCO 204.08
- EDSA N/A
- 52 Week Low
- RMCO $0.76
- EDSA $1.55
- 52 Week High
- RMCO $1.88
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- RMCO 52.78
- EDSA 55.09
- Support Level
- RMCO $1.23
- EDSA $2.03
- Resistance Level
- RMCO $1.54
- EDSA $2.11
- Average True Range (ATR)
- RMCO 0.15
- EDSA 0.10
- MACD
- RMCO 0.00
- EDSA 0.01
- Stochastic Oscillator
- RMCO 20.29
- EDSA 73.33
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.